cas 1211443-61-6|| where to buy 2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

製品名:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

IUPAC Name:2-chloro-7-cyclopentyl-N,N-dimethyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxamide

包装単位	有効在庫	価格（USD）
CM103621-5g	in stock	ŉǤ
CM103621-10g	in stock	ƥŗŉ
CM103621-25g	in stock	ŗȃŹ
CM103621-100g	in stock	ŉƥȃ

研究開発用専用.

問い合わせフォーム

化学物質名

CAS番号

数量*

要求仕様*
（アッセイ %、材料グレード等）

お名前*

連絡先Eメールアドレス*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 1211443-61-6 regularly via the above email.

追記事項

Verification code*

refresh

: CAS番号:1211443-61-6; 分子式:C14H17ClN4O; 融点:-; SMILESコード:CN(C)C(=O)C1=CC2=C(N=C(Cl)N=C2)N1C1CCCC1; 密度:

: カタログ番号:CM103621; 分子量:292.77; 沸点:; MDL番号:MFCD20527881; 保管方法:

: Pyrrolopyrimidines; Fusion heterocyclic compounds have various biological activities, such as anticancer, antibacterial, antifungal and anti-inflammatory, and thus have been widely used in the field of medicinal chemistry. Pyrrolopyrimidines are a major class of fused heterocyclic compounds. Compared with single pyrrole and pyrimidine cores, pyrrolopyrimidines have more diverse and effective pharmacological characteristics as fusion scaffolds.

: Cyclopentanes; Cyclopentane is a cycloalkane, an organic compound with a molecular formula of C5H10, a colorless and transparent liquid, insoluble in water, soluble in most organic solvents such as ethanol, ether, benzene, carbon tetrachloride, acetone, etc. It is mainly used as a solvent and chromatographic reference materials.; Cyclopentanes,where to buy Cyclopentanes; Cyclopentanes; Cyclopentane (also called C pentane) is a highly flammable alicyclic hydrocarbon with chemical formula C5H10 and CAS number 287-92-3, consisting of a ring of five carbon atoms each bonded with two hydrogen atoms above and below the plane. It occurs as a colorless liquid with a petrol-like odor.

: Ribociclib; FDA has approved Novartis Kisqali(ribociclib) to reduce risk of recurrence in people with hormone receptor-positive/human epidermal growth factor receptor 2-negative(HR+/HER2-) early breast cancer (EBC).
Kisqali is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Beyond today’s FDA approval of Kisqali for EBC patients in the US, regulatory reviews for Kisqali as an EBC treatment are ongoing worldwide, including in the EU and China.